Hematology

At the department of Hematology we are dedicated to improving the diagnosis and treatment of patients with hematological diseases. We perform basic and translational research to generate insight into the pathobiology of hematological diseases, and translate these findings into novel treatments for our patients.

In addition, we direct a wide variety of clinical studies, closely linked to our preclinical programs. These clinical studies deal with the development of molecular diagnostics, advancement of allogeneic stem cell transplantation, circumvention of drug-resistance to chemotherapy as well as a broad range of clinical phase I to phase III trials for a variety of hematological diseases.

For more information on specific research lines please select a principle investigator from the list below or select a particular hematological disease in the list of research lines.

For more information on clinical care for patients with hematological diseases please see our clinical homepage.

Follow this link to see all our studies.

• Ruben Bierings
• Eric Braakman
• Jan Cornelissen
• Tom Cupedo
• Mojca Jongen-Lavrencic
• Ruud Delwel
• Frank Leebeek
• Bob Löwenberg
• Moniek de Maat
• Emma de Pater
• Marc Raaijmakers 
• Dick Rijken
• Rebekka Schneider-Kraman 
• Pieter Sonneveld
• Ivo Touw 
• Peter Valk

Acute Myeloid Leukemia (AML)

• Ruud Delwel
• Mojca Jongen-Lavrencic
• Bob Löwenberg
• Peter Valk

Bone Marrow Fibrosis

• Rebecca Schneider-Kraman

Severe Congenital Neutropenia

• Ivo Touw

Hematopoiesis and Stem Cell Transplantation

• Eric Braakman
• Jan Cornelissen
• Emma de Pater

Hemostasis & Thrombosis

• Ruben Bierings
• Frank Leebeek
• Monique de Maat
• Dick Rijken

Myelodisplastic Syndrome

• Marc Raaijmakers
• Rebecca Schneider-Kraman

Multiple Myeloma

• Tom Cupedo
• Pieter Sonneveld

Grant Department Hematology ErasmusMC for single cell analyses in hematologic malignancies

The Hematology department has received a grant of €100.000 from the Stichting Leukemie (www.leukemie.nl) for single cell analysis of hematological malignancies, in particular acute myeloid leukemia (AML).

AML is an example of a heterogeneous group of hematologic malignancies with a variable response to therapy. The heterogeneity of AML is illustrated by the different (combinations of) mutations that occur with AML. Based on these mutations the prognosis of the AML patient can be estimated. However, despite the fact that prognostics in AML has greatly improved in recent decades, there is still much to be learned.

Residual disease during therapy of a haematological malignancy is a good predictor for getting recurrence of disease. We have recently demonstrated that the use of next generation sequencing in residual disease detection greatly improves the quantitative prediction of a recurrence (M. Jongen et al., NEJM 378, 2018).

The analyses in the above study were performed on the bulk of the AML cells. Analysis of DNA abnormalities at the level of a single cell will ultimately be necessary to determine which cells within a heterogeneous population of cells are critically important for the return of the AML. The grant from the Stichting Leukemie will be used to purchase equipment for the analysis of residual disease in AML at the single cell level.